Phase III Clinical Study of Azvudine in Hiv-infected Treatment Naive Patients
Status:
Not yet recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
Azvudine,(FNC)， new nuclear nucleoside reverse transcriptase inhibitors, FNC make itself a
better candidate to be co-formulated in other anti-HIV therapies, thus to improve patient's
compliance, approved by state drug administration (NMPA) for clinical research. FNC has
completed its phase I、II clinical studies with desirable results.This is a multi-center,
randomized, double-blind,double-placebo,active-control clinical trial. Subjects in
experimental arm receives FNC+TDF+EFV+3TC placebo, while the subjected in active control arm
receives 3TC+TDF+EFV+FNC placebo. The background drugs in both arms are conducted in
open-label design while FNC and 3TC are conducted in double-blinded design.